Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00203528 · ClinicalTrials.gov registry record · Phase 4
Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder
A Phase 4 study, sponsored by Tuscaloosa Research & Education Advancement Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00203528 is a Phase 4 study that has completed, run by Tuscaloosa Research & Education Advancement Corporation. The registered enrollment target is 30 participants.
The verdict
NCT00203528, a Phase 4 study, has completed, sponsored by Tuscaloosa Research & Education Advancement Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the safety and efficacy of divalproex extended release (ER) compared to risperidone in the treatment of bipolar disorder with comorbid substance use disorder
Interventions
- DRUG risperidone
- DRUG divalproex sodium ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-01 |
| Est. Completion | 2007-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00203528
The ClinicalTrials.gov registry entry for NCT00203528 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tuscaloosa Research & Education Advancement Corporation, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00203528 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00203528 about?
NCT00203528 is a clinical study titled "Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder". The primary objective is to evaluate the safety and efficacy of divalproex extended release (ER) compared to risperidone in the treatment of bipolar disorder with comorbid substance use disorder
What is the current status of trial NCT00203528?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2004-01. Estimated completion is 2007-02.
What interventions are being tested in trial NCT00203528?
The interventions under investigation include: risperidone (DRUG), divalproex sodium ER (DRUG).
Who is sponsoring clinical trial NCT00203528?
This trial is sponsored by Tuscaloosa Research & Education Advancement Corporation, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.